Sonnet biotherapeutics announces release of the next ceo corner segment

Princeton, nj, dec. 23, 2024 (globe newswire) -- sonnet biotherapeutics holdings, inc. (the “company” or “sonnet”) (nasdaq: sonn), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next ceo corner segment has been published on the company's website .
SONN Ratings Summary
SONN Quant Ranking